152 Chapter 7 HPV-vaccinated cervical lesions Controls (n = 371) LSIL (n = 15) HSIL (n = 17) Year of birth 1992 89 (24.1%) 3 (20.0%) 7 (41.2%) 1993 45 (12.2%) 3 (20.0%) 3 (17.7%) 1994 151 (40.9%) 5 (33.3%) 7 (41.2%) 1995 84 (22.8%) 4 (26.7%) - Vaccination age (Mean (±SD)) 14.55 (±0.69) 14.68 (±0.20) 14.96 (±0.13)† HPV HPV negative 230 (62.0%)†‡ 2 (13.3%)‡ 2 (11.7%)† Any HPV+ 141 (38.0%)†‡ 13 (86.7%)‡ 15 (88.2%)† hrHPV+ 98 (26.4%)†‡ 12 (80.0%)‡ 15 (88.2%)† lrHPV+ 72 (19.4%) 5 (33.3%) 4 (23.5%) Single HPV 81 (21.8%) 4 (26.7%) 6 (35.3%) Multiple HPV 2+ 60 (16.2%)†‡ 8 (53.3%)‡ 9 (52.6%)† Multiple HPV 2 49 (13.2%) 4 (26.7%) 5 (29.4%) 3 8 (2.2%) 3 (20.0%) 3 (17.7%) 4 2 (0.5%) 2 (13.3%) 1 (5.9%) 5 1 (0.3%) - - HPV genotypes by groups ^ Group 1 - Carcinogenic HPV16 1 (0.3%) - - HPV33 4 (1.1%)† - 3 (17.7%)† HPV35 2 (0.5%) - 1 (5.9%) HPV39 4 (1.1%) 2 (13.3%) 1 (5.9%) HPV45 1 (0.3%) - - HPV51 15 (4.0%)†‡ 7 (46.7%)‡ 4 (23.5%)† HPV52 23 (6.2%)† 1 (6.7%) 5 (29.4%)† HPV56 14 (3.8%) 1 (6.7%) 1 (5.9%) HPV58 6 (1.6%)† 1 (6.7%) 4 (23.5%)† HPV59 12 (3.2%)†‡ 5 (33.3%)‡ 4 (23.5%)† Group 2a and 2b - Possibly and probably carcinogenic HPV30 5 (1.4%) - - HPV34 - - - HPV53 3 (0.8%) 1 (6.7%) - HPV66 12 (3.2%) 2 (13.3%) 1 (5.9%) HPV67 6 (1.6%) 1 (6.7%) - Table 7.1 Characteristics of 403 women included in the nested case-control study at the age of 25 years during follow-up visit from the Finnish community and individually randomised trial cohorts.
RkJQdWJsaXNoZXIy MjY0ODMw